Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting

Manoj Chadha · Ashok Kumar Das · Prasun Deb · Kalyan Kumar Gangopadhyay · Shashank Joshi · Jothydev Kesavadev · Rajiv Kovil · Surender Kumar · Anoop Misra · Viswanathan Mohan

Received: February 4, 2021 / Accepted: February 1, 2022 / Published online: March 25, 2022 © The Author(s) 2022

ABSTRACT

The Asian-Indian phenotype of type 2 diabetes mellitus is uniquely characterized for cardiometabolic risk. In the context of implementing patient-centric holistic cardio-metabolic risk management as a priority, the choice of various combinations of antidiabetic agents should be individualized. Combined therapy with two classes of antidiabetic agents, namely, dipeptidyl peptidase 4 inhibitors and sodium-glucose co-transporter-2 inhibitors, target several pathophysiological pathways. The wide-ranging clinical outcomes associated with this combination, including improvement of glycemia and adiposity, reduction of metabolic and vascular risk, safety, and simplicity for sustainable compliance, are extremely relevant to the Asian Indian patient population living with T2DM. In this review we describe the available evidence in detail and present a rational
practical guidance for the optimum clinical use of this combination in this patient population.

**Keywords:** Asian Indian phenotype; Type 2 diabetes; Cardio-metabolic risk; Sodium-glucose cotransporter-2 inhibitor; Dipeptidyl peptidase-4 inhibitor; Fixed-dose combinations

### Key Summary Points

**Why this expert opinion?**

This expert opinion serves as a clinical guidance for the optimum use of the therapeutic combination of dipeptidyl peptidase 4 inhibitor (DPP4i) + sodium-glucose co-transporter-2 inhibitor (SGLT2i) in the management of Asian Indian patients with type 2 diabetes mellitus (T2DM).

The Asian Indian phenotype is characterized by increased visceral adiposity, lower metabolic tolerance, and increased cardio-renal risk.

A personalized approach that is relevant to the unmet needs of each individual patients should be the underlying principle for clinical decision.

It is important to address multiple pathophysiological aspects underlying T2DM; combination therapy with a DPP4i + SGLT2i may be relevant in this regard.

This therapeutic combination may be a pertinent partner to metformin, in providing meaningful glycemia control without increasing risk for hypoglycemia, and in improving the metabolic profile of patients.

The combination of agents with proven benefits may be preferred for patients with higher predisposition to cardiovascular events and kidney disease.

Overcoming clinical inertia and ensuring long-term adherence are important aspects of clinical outcomes optimization; the adoption of a relevant combination therapy can help address these aspects.

### INTRODUCTION

India has the second highest number of people (77 million) with type 2 diabetes mellitus (T2DM) in the world. The large Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study, which is a nationally representative epidemiological study, is currently being conducted throughout the country in a phased manner [1, 2]. To date, the findings suggest an increasing prevalence of T2DM in both urban and rural areas, but with a comparatively steeper rise in the urban setting that is driven by rapid changes in dietary practices and greater physical inactivity compared to rural areas. A particularly alarming trend observed in India is the shift in onset of diabetes to people in younger age groups. In the ICMR-INDIAB study (Phase I), the demographic increase in T2DM was evident in the 25- to 34-year age group, and declined after age 65 years [2]. Of all patients with T2DM in India, the study found that 69% had not achieved the target level of HbA1c. Non-compliance to lifestyle measures and multiple other factors are responsible for nonattainment of glycemic control in Indians [3].

The unmet need of improving/achieving the glycated hemoglobin (HbA1c) goal is strongly associated with the requirement for diverse therapeutic options, namely, for the individualization of care (personalized medicine). Clinicians are currently witnessing a greater choice of therapeutic options, which may be also useful in various combinations to address specific priorities. At the same time, polypharmacy, with its increased pill burden and dosing frequency, is inherently associated with poorer treatment adherence [4, 5]. Even in countries with high access to healthcare, only 39% patients have reported good medication adherence. In a study of 2741 patients on oral antidiabetic drugs, each 10% increase in oral diabetes medication adherence was associated with a 0.1% decrease in HbA1c (P = 0.0004). There is evidence suggesting that treatment-adherent patients are more likely to achieve better glycemic control than non-adherent patients [5].
The Indian diabetes setting is also overwhelmed with a plethora of fixed-dose drug combinations (FDCs) for T2DM. The Indian pharmaceutical industry markets > 50 such FDCs in more than 500 brand names. The Drug Controller General of India (DCGI) has recently scrutinized this situation, and citing lack of therapeutic justification, banned 344 such FDCs (27 of which were metformin-based FDCs). While rational FDCs do help in improving drug adherence as well as treatment outcomes, it is important that there be a sound justification for such combinations [4].

In this context, a rational and synergistic FDC of antidiabetic drugs may be considered as a prudent option. In addition to reducing pill burden and improving compliance, combination therapy with two drugs may help patients achieve their target HbA1c faster than monotherapy. Early intensive therapeutic control has proven benefits in clinical outcomes. Long-term studies, such as, for example, the UK Prospective Diabetes Study (UKPDS), have suggested that good glycemic memory leads to a significant reduction in any diabetes-related endpoint. The long-term follow-up of the UKPDS study showed a significant 24% reduction in microvascular disease and a 15% reduction in macrovascular complications, such as myocardial infarction, along with a 13% reduction in all-cause mortality [6]. Results from the long-term follow-up of Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, the Action in Diabetes and Vascular disease study, the PreterAx and Diamicron-MR Controlled Evaluation (ADVANCE) study, and the Veterans Affairs Diabetes Trial (VADT) also suggested improvements in microvascular outcomes with early intensive glycemia control; however, the macrovascular and mortality outcomes were not consistently improved in these studies. Despite intensive glycemia control having proven clinical benefits for several outcomes, the residual risk of cardiovascular (CV) death has remained a significant unmet need in patients with T2DM. Since 2015, a number of glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated improved CV outcomes regardless of glycemia control; these agents now form an essential part of the armamentarium for appropriate cardio-metabolic risk management in T2DM [7]. With this increased availability of therapeutic choices that may address various unmet priority needs, the question of ‘rational combination(s)’ in T2DM holds deeper and broader implications today. In the current setting of the COVID-19 pandemic, good glycemic control (along with control of other risk factors) has been shown to reduce morbidity and mortality in patients with T2DM [8].

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

UNMET NEEDS AND SCOPE

The four pressing unmet needs in the management of T2DM, within the scope of this paper, include:

1. A need for a combinatorial approach to address multiple pathophysiological mechanisms of hyperglycemia, thus effecting a robust glycemic control.
2. A need for additional treatments that provide both glycemic and non-glycemic benefits, especially since the control of diabetes comorbidities is less than optimal in most patients.
3. Reducing the occurrence of hypoglycemia or weight gain, as recurrent distressing side effects of traditional antidiabetic agents reduces the morale of not only the patient but also the treating physician.
4. An oral treatment option that not only meets all of the pressing needs but additionally improves the compliance of the patients in need.

A synergistic and rational FDC of a SGLT2i and a dipeptidyl peptidase-4 inhibitor (DPP4i), such as an empagliflozin (SGLT2i) and linaagliptin (DPP4i) FDC, may address these unmet needs. These issues are elaborated in detail in the subsequent sections of this review.
AIM AND APPROACH IN DEVELOPING THE EXPERT OPINION PAPER

The aim of this expert opinion paper is to evolve an evidence-based clinical guidance for the appropriate consideration and use of combination therapy with SGLT2i + DPP4i, for patients with T2DM in the routine clinical practice setting, in India. With this aim ten experts in the field of diabetes across India came together and developed a pragmatic approach for the optimum use of SGLT2i + DPP4i in FDCs for patients with T2DM through extensive literature reviews and one round of deliberate discussion on available evidence for this class of agents.

PATHOPHYSIOLOGICAL APPROACH TO DIABETES MANAGEMENT

The “ominous octet” is the pathophysiological core of the mechanism of diabetes. As depicted in Fig. 1, various classes of agents act differently on different components of the “ominous octet”.

A “pathophysiological approach” using initial combination therapy with agents known to address the established defects in T2DM seems more rational. It is preferable to use combination therapies having complementary mechanisms of action that target different pathways addressing the multiple pathophysiologic abnormalities of T2DM [10–12]. The complementary beneficial effect of this combination is depicted in Fig. 2.

The presence of multiple pathophysiologic abnormalities dictate several important implications in the management of patients with T2DM [10, 14, 15].

- Multiple drugs in combination may be required to manage the various pathophysiologic abnormalities.
- Drugs that target the known pathophysiologic processes and help to counteract or reverse them should be considered.
- Treatment should not be based on mere reduction of HbA1c, or just controlling fasting/postprandial blood glucose.
- Intensive treatment should be started early to prevent or halt the progression of β-cell failure.
- Few of the various pathophysiological abnormalities can be targeted with multiple antihyperglycemic agents, while few of the agents can target multiple pathways as well.

Time-in-range (TIR) is the percentage of time in a 24-h period when glucose levels remain between 70–180 mg/dL. Evidence suggests that TIR complements HbA1c as a parameter of glycemic control, with higher TIR associated with better clinical outcomes [16]. Studies with SGLT2i agents as well as DPP4i agents suggest that these drugs have beneficial effects on TIR. The SGLT2i anti-hyperglycemic agents influence fasting as well as the postprandial components of glycaemia, and DPP4i antihyperglycemic agents have more prominent effects on postprandial hyperglycemia; both of these classes of medications are associated with lower risks for hypoglycemia. Glycemic variability (GV) has been an emerging target for preventing complications related to T2DM. Systematic reviews and meta-analyses of 16 randomized controlled trials (RCTs) with SGLT2i and seven RCTs of DPP4i have demonstrated that these agents reduce glycemic variability in patients with T2DM [17, 18]. The Time in Range recommendations for South Asia suggests frequency for repeating TIR evaluation, which may be minimal for therapies such as SGLT2i and DPP4i with minimal glycaemic variability again reducing the cost and complications [19].

- In addition, several RCTs have shown that the DPP4i are also associated with lower insulin dose requirements [17–19].

Thus, the combined use of SGLT2i/DPP4i agents (either separately or as a FDC) not only provides medications that complement each other well, but also targets at least six of the eight components in the “ominous octet” [20]. Hence after metformin initiation or even prior to metformin initiation in suitable patients
(metformin contraindicated or intolerant), or in patients with high HbA1c who fail on metformin, this combination may give excellent “treat-to-target” benefit to the patients, thus facilitating the “treat early and treat right” approach.

Fig. 1 The “ominous octet” of type 2 diabetes mellitus and the target sites for glucose-lowering therapies. DDP-4i Dipeptidyl peptidase-4 inhibitor, GLP-1RA glucagon-like peptide-1 receptor agonist, SGLT2i sodium-glucose co-transporter-2 inhibitors. (Adapted from Chatterjee and Davies [9])

Fig. 2 Illustration of the complementary glucose-lowering activities of DPP4i and SGLT2i in type 2 diabetes mellitus. GIP Glucose-dependent insulino-tropic polypeptide, SBP systolic blood pressure. (Adapted from Scheen [13])
AVAILABLE PRE-CLINICAL AND CLINICAL EVIDENCE WITH SGLT2I AND DPP4I AGENTS

Pre-Clinical Evidence

A study on isolated human islet cells showed that linagliptin restored β-cell function and turnover, which was impaired when islets were exposed to elevated glucose [21]. This demonstrated a direct GLP1-mediated protective effect of linagliptin on β-cell function and survival. Linagliptin was shown to prevent β-cell apoptosis in metabolic and inflammatory stress conditions through the anti-inflammatory interleukin receptor antagonist (IL-1RA) [21].

A study on Wistar rats showed that linagliptin reduced infarct size in an acute model of myocardial infarction by causing an increase in stromal cell-derived factor 1α (SDF-1α) and the respective receptor in infarcted tissue, providing evidence for stem cell recruitment [22]. Linagliptin also improved diastolic function and significantly reduced markers of fibrosis of the heart in a setting of uremic cardiomyopathy [23].

Overall, pre-clinical research on linagliptin has yielded several interesting findings over and above glycemic efficacy, safety, and beta cell preservation. Improved wound healing, reduced inflammation, reduced hepatic fat content, decreased infarct size following myocardial infarction or intracranial stroke, improved vascular function with decreased oxidative stress, improved endothelial dysfunction, and lowering of albuminuria have also been observed in pre-clinical studies [24].

Mechanistic studies suggest that the potential direct cardiovascular benefits of SGLT2i include augmentation of signal transducer and activator of transcription 3 (STAT3), inhibition of sodium hydrogen exchange (sodium-hydrogen antiporter 1 [NHE-1]), improved mitochondrial metabolism, modulation of natriuretic peptides, improved vascular stiffness and autonomic tone, reduction of inflammation, and improved cardiac energetics. There are a few intermediate effects by which SGLT2i may exert cardiovascular benefits that extend beyond glycemic control [25–28].

Clinical Evidence in Asian Indian Patients

The Indian “thin fat” phenotype is more prone to the development of T2DM and is associated with several unique features, such as early age of T2DM onset, early decline in beta cell mass, higher insulin resistance, higher carbohydrate intake and physical inactivity leading to central obesity, unique dyslipidemia pattern, increased CV disease risk, higher association with nonalcoholic fatty liver disease, among others [29–31]. DPP4i have been shown to exert higher efficacy in Asian patients, probably due to increased DPP4 enzyme activity in Asian Indian patients with T2DM [32]. A study comparing the pharmacodynamics, efficacy, and safety of linagliptin among Japanese, Asian, and White patients with T2DM showed that a better reduction in HbA1c was achieved in the Asian patients as compared to the Caucasians, without any added safety issue [33]. In another study, linagliptin effectively reduced hyperglycemia in Asian patients with uncontrolled T2DM, irrespective of age, body mass index, renal function, or ethnic subgroup, and was well tolerated [34].

A recent meta-analysis showed that SGLT2i and, to a lesser extent, DPP4i are associated with greater glucose-lowering efficacy in patients from Asian ethnicity [35]. Subgroup analysis from the EMPA-REG OUTCOME study demonstrated consistent risk reductions for CV outcomes, mortality, and renal outcomes with empagliflozin in Asian patients with T2DM and established CV disease [36–40].

SGLT2i + DPP4i FDCs: Clinical Evidence Overview

Three SGLT2i + DPP4i FDCs are currently by the US Food and Drug Administration (USFDA), but only two of these are approved for use and commercially available in India. These FDCs have been approved as an adjunct to diet and exercise to improve glycemic control in adults
with T2DM when treatment with both an SGLT2i and DPP4i is appropriate (Table 1).

**Efficacy of SGLT2i + DPP4i FDCs**

Evidence from numerous clinical trials suggest that SGLT2i + DPP4i FDCs are effective and safe in controlling glycemic parameters in patients with T2DM. The efficacy of the available FDCs were evaluated in long-term studies in patients with T2DM on metformin monotherapy and treated with diet and exercise. The efficacy of the empagliflozin + linagliptin FDC was also evaluated in drug-naïve patients [46–50].

Certain anecdotal studies have been conducted in Japan on the effect of sequential therapy with a combination of canagliflozin and teneligliptin in patients with T2DM [46, 47]. However, since the FDC has not been approved in major markets like the USA, Europe, and India, the evidence from these studies is beyond the scope of this review.

**Initial Combination in Drug-Naïve Patients with T2DM** The reduction of HbA1c in drug-naïve patients receiving different SGLT2i + DPP4i FDCs are compared in Table 2.

**As an Add-on to Metformin Monotherapy** The reduction in HbA1c in T2DM patients on metformin monotherapy with SGLT2i + DPP4i FDCs is compared in Table 3.

Studies have shown a consistent reduction in body weight and blood pressure in the SGLT2i monotherapy arm and the FDC arm [49–56].

**Safety Evidence**
The overall safety profile of the FDCs was similar to those of the individual components. There were no significant differences in

---

**Table 1** Global and Indian approval status of sodium-glucose co-transporter-2 inhibitor + dipeptidyl peptidase-4 inhibitor fixed-dose combinations

| Fixed-dose combination          | USFDA approval | DCGI (CDSCO) approval | Commercial availability in India |
|---------------------------------|----------------|-----------------------|---------------------------------|
| Empagliflozin + linagliptin FDC | Yes (2015) [41]| Yes (2017) [44]       | Yes (2018)                      |
| Dapagliflozin + saxagliptin FDC | Yes (2017) [42]| Yes (2019) [44]       | Yes (2020)                      |
| Ertugliflozin + sitagliptin FDC | Yes (2017) [43]| No                    | No                              |
| Remogliflozin + vildagliptin FDC| No             | Yes (2020) [45]       | Yes (2020)                      |
| Canagliflozin + teneligliptin FDC| No            | No                    | No                              |

*CDSCO* Central Drugs Standard Control Organization, *DCGI* Drug Controller General of India, *FDC* fixed-dose combination, *USFDA* US Food and Drug Administration

---

**Table 2** Reductions in glycated hemoglobin from baseline in drug-naïve patients with type 2 diabetes mellitus

| HbA1c reduction | Empagliflozin + linagliptin FDC | Dapagliflozin + saxagliptin FDC | Ertugliflozin + sitagliptin FDC |
|-----------------|---------------------------------|---------------------------------|---------------------------------|
|                 | [48]                            | [49]                            |                                 |
| 10 mg/5 mg      | 25 mg/5 mg                      | 10 mg/5 mg                      | 5 mg/100 mg                     |
| HbA1c reduction | 1.2% (baseline 8%)              | 1.1% (baseline 8%)              | 1.3% (baseline 8.3%)            |
|                 | No evidence                     | No evidence                     | No evidence                     |
| HbA1c reduction | 1.9% (baseline 9.3%)            | 1.9% (baseline 9.2%)            | 2.2% (baseline 9.6%)            |
|                 | No evidence                     | No evidence                     | No evidence                     |

No head-to-head comparison data are available

*HbA1c* Glycated hemoglobin
hypoglycemia events, urinary tract infections, or events related to hypovolemia and ketoacidosis. Interestingly, slightly lower rates of genitourinary tract infections (GTIs) were reported with the FDC as compared to SGLT2i monotherapy. Some of the probable reasons for such moderation of GTIs with the FDC, beyond improved glycemic control, may be the interaction of DPP4 and SGLT2 proteins at the renal tubular cell-membrane level, or the inhibition of the DPP4 enzyme present in certain pathogenic microbes that may render them inactive (Fig. 3) [52].

### Table 3 HbA1c response in patients with type 2 diabetes mellitus on metformin monotherapy

| HbA1c reduction | Empagliflozin + linagliptin FDC [50] | Dapagliflozin + saxagliptin FDC [53] | Ertugliflozin + sitagliptin FDC [55] |
|------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                  | 10 mg/5 mg                          | 25 mg/5 mg                          | 10 mg/5 mg                          |
|                  | 5 mg                                | 100 mg                              | 100 mg                              |
| HbA1c reduction (%) (mean baseline < 8.5%) | -1.1% - 1.2% | NA | NA |
| HbA1c reduction (%) (mean baseline > 8.5%) | -1.6% - 1.8% | -1.5% | -1.5% |

No head-to-head comparison data are available

NA Data not available

Safety with Simultaneous SGLT2i + DPP4i FDC as Compared to Sequential Addition of SGLT2i to DPP4i Therapy

A systematic review and meta-analysis of seven RCTs [57] involving 2082 participants with a duration of at least 12 weeks) investigated the effect of SGLT2i + DPP4i therapy in patients with T2DM.

All seven studies assessed the risk of urinary tract infections (UTIs) and GTIs at the end of the treatment. The risk of an UTI was found to be slightly higher in group receiving sequential combination therapy (relative risk [RR] 0.96, 0.95–1.00) compared to group receiving the FDC (RR 0.80, 0.75–0.85).

![Fig. 3](Fig3.png) Incidence of genitourinary tract infections favors the use of the SGLT2i + DPP4i fixed-drug combination. CI Confidence interval, GTI genitourinary tract infection, RR relative risk. (Adapted from Fadini et al. [52])

△ Adis
The risk of a GTI was also higher in the sequential combination group (RR 5.57, 95% CI 2.33–13.33) than in simultaneous group (RR 1.35, 95% CI 0.55–3.34) [57].

Overall, the results of this analysis suggest a possible lower risk of GTIs and nominal reduction in incidence of UTIs with simultaneous combination as opposed to sequential combination of SGLT-2i and DPP-4i.

Summary of CV and Renal Outcomes with SGLT2i and DPP4i Agents

**SGLT2: Inhibitor Cardiovascular Outcome Trials**

Cardiovascular outcome trials (CVOTs) have consistently shown that treatment with SGLT2i reduces hospitalization for heart failure (HHF) and secondary renal outcomes in terms of incident or worsening nephropathy in patients with T2DM and CV disease. To date no CVOT has been carried out on remogliflozin. Some differences in 3-point major adverse cardiac event (3P-MACE) and CV death endpoints among patients on SGLT2i have been shown in the CVOTs [58–62], as shown in Table 4.

In patients with T2DM and established CV disease, empagliflozin and canagliflozin have been shown to reduce the of MACE events, although only empagliflozin has demonstrated an ability to reduce the risk of CV death in this population. All SGLT2i CVOTs carried out to date have demonstrated a consistent risk reduction for heart failure-related hospitalizations in patients with established CV disease or high CV risk. The Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) study demonstrated significant improvement in renal outcomes with canagliflozin in patients with T2DM and advanced macro-albuminuric kidney disease, as compared to placebo [63].
DPP-4i CVOTs
With respect to the primary endpoint (3P-MACE), the CV safety profile of saxagliptin, sitagliptin and linagliptin was established in the respective CVOTs [64–66]. However, there was a heterogeneity seen in the risk for HHF. Saxagliptin showed an increased risk for HHF, whereas both sitagliptin and linagliptin had no increase in the risk of HHF in the respective CVOTs. Vildagliptin does not have a dedicated CVOT, however, in the VIVIDD study, an increase in end systolic and diastolic volumes was noted [67]. Teneligliptin, also does not have a CVOT and may prolong the QT interval at higher doses and needs to be administered with caution [68].

The cardiovascular and renal outcomes of DPP4i have been summarized in Table 5.

Hepatic Safety with SGLT2i and DPP4i

SGLT2i
Meta-analysis and review reports from large phase II–III trials showed that SGLT-2i do not cause hepatotoxicity [65, 66, 69, 70]. No dose adjustment is required in mild to moderate liver dysfunction.

DPP4i
It is recommended that with the exception of vildagliptin, other DPP-4 inhibitors can be used without dose modification in patients with Child–Pugh Class A liver disease, while their use requires caution in those with Class B disease and is not preferred in patients with severe liver dysfunction (Class C) [74–76].

EXPERT OPINION
The SGLT2i +DPP4i FDCs have been available in India since their introduction in 2018. These are unique non-metformin-based FDCs, which is why there is no clear guidance on their place in T2DM management. The scope of this expert

Table 5 Cardiovascular and renal outcomes with DPP-4 inhibitors in cardiovascular outcome trials

| Clinical outcomes | Cardiovascular outcome trials | TECOS [65] (sitagliptin) | CARMELINA [66] (linagliptin) |
|-------------------|--------------------------------|--------------------------|-----------------------------|
|                   | SAVOR TIMI 53 [64] (saxagliptin) |                          |                             |
| HHF               | HR 1.27c (95% CI 1.07, 1.51)    | HR 1.00c (95% CI 0.83, 1.20) | HR 0.90c (95% CI 0.74, 1.08) |
| CV death          | HR 1.03 (95% CI 0.87, 1.22)     | HR 1.03 (95% CI 0.89, 1.19)  | HR 0.96 (95% CI 0.81, 1.14)  |
| 3P-MACE           | HR 1.00d (95% CI 0.89, 1.12)    | HR 0.99d (95% CI 0.89, 1.10) | HR 1.02d (95% CI 0.89, 1.17) |
| Renal outcomesb  | Limited evidence                | Limited evidence          | HR 1.04c (95% CI 0.89, 1.22) |

Cells with underlining represent significant observations

SAVOR TIMI 53, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction; TECOS, Trial Evaluating Cardiovascular Outcomes with Sitagliptin; CARMELINA Cardiovascular and Renal Microvascular Outcome Study With Linagliptin

bComposite of end-stage kidney disease, renal death, or ≥ 40% decrease in estimated glomerular filtration rate
cExploratory outcome
dTesting for superiority for 3P-MACE was the primary endpoint (4P-MACE for sitagliptin)
(a) Appropriate Use of SGLT2i/DPP4i FDC Based on Glycemic factors

Management of T2DM

1. In Treatment Naive patients
   Where Metformin is contraindicated/ intolerance & HbA1c >8%

2. In Treatment Naive (with Metformin) patients
   In combination with Metformin in patients where baseline HbA1c is high (>9%)

3. Uncontrolled on Metformin monotherapy
   In patients uncontrolled on Metformin with HbA1c >8.5%

(b) Appropriate Use of SGLT2i/DPP4i FDC Based on Glycemic Control

Management of T2DM

4. Uncontrolled on Met + 2nd Line
   Use in place of DPP4i or SGLT2i when HbA1c > 7.5%

5. Uncontrolled on Met + 2nd line agents (Exclude DPP4i/SGLT2i)
   a) Add this FDC when HbA1c is 8.5% on other glucose-lowering medications
   b) Replace when HbA1c is above 7.5%. This should be individualized for each patient

6. Add on to Insulin
   This combination may be used as an add on to insulin, with an individualised approach, ensuring appropriate titration of insulin

(c) Based on CV risk including Heart Failure

HbA1c criteria applicable as above

SGLT-2 inhibitors

SGLT-2i with proven CV & HF benefits are preferred agents in cases with cardiovascular disease, including heart failure.

DPP-4 inhibitors

DPP-4i with proven CV & HF safety such as Linagliptin and Sitagliptin have shown a favourable CV safety profile including no increased risk of hospitalisations due to heart failure in their CVOTs.

This combination may be preferred over other conventional therapies (those with no CV benefit) in cases of established CV disease and/or Heart Failure risk.
opinion is to aid in clinical decision-making for the appropriate use of the SGLT-2i and DPP-4i FDCs in T2DM management.

Metformin remains the first-line pharmacological approach to the treatment of T2DM, along with lifestyle modification, with the exception of cases where metformin is not tolerated or contraindicated. Patient preference and clinical characteristics should influence the choice of a second-line glucose-lowering medication. Since the absolute effectiveness of most oral medications rarely exceeds a 1% reduction in HbA1c, the initial combination therapy with a SGLT-2i + DPP-4i FDC may be considered in patients presenting with high HbA1c levels (1.5% above individualized target). In addition, the presence of comorbidities and established CV and kidney safety and/or benefits of
antidiabetic agents may mandate their choice over other conventional options. With the evolving evidence and guidelines across the world, we should now choose second-line agents such as SGLT2i and GLP1-RAs with proven CV benefits in patients with high CV risk followed by agents with proven CV safety if additional glycemic control is required. The combination of an SGLT2i and DPP4i may, therefore, become more relevant in patients with high CV risk and/or heart failure risk who have HbA1c > 1.5% above the individualized target.

Medications with good glycemic efficacy and a low risk of hypoglycemia and weight loss help to intensify the treatment without introducing common adverse events, such as hypoglycemia and weight gain. These advantages may help overcome clinical inertia for treatment intensification. Targeting multiple pathophysiological pathways for T2DM with DPP4i + SGLT2i combination therapy is a clear benefit which also supports the use of this combination early in T2DM management.

A SGLT2i + DPP4i FDC is a suitable option for Indian T2D patients, for the following reasons:

- Safer, rapid, and sustained glycemic control
- Improves both insulin resistance and beta cell function
- Helps reduce body weight and blood pressure (extraglycemic benefits)
- Reduces pill burden (adherence and compliance improves)
- Overall cost effective

The following decision-making algorithms (Fig. 4a–e) may help guide the use of a SGLT2i + DPP4i combination in clinical practice. Decisions on appropriate use may be made taking into consideration the glycemic parameters together with the status of CV and renal comorbidity and clinically relevant considerations, such as risk of hypoglycemia and weight gain. In treatment-naïve patients with T2DM for whom metformin is contraindicated or who are metformin intolerant and HbA1c is > 8% (as per the inclusion criteria of SGLT2i + DPP4i FDC RCTs), we recommend initiating combination therapy with a SGLT2i + DPP4i FDC along with lifestyle modification (Fig. 4a).

ACKNOWLEDGEMENTS

**Funding.** This academic initiative has been facilitated by Boehringer Ingelheim India. The journal’s Rapid Service Fee was also supported by Boehringer Ingelheim India Pvt. Ltd.

**Medical Writing Assistance.** The authors thank Manthan Mehta, Kumardeep Paul, Syed Rahman, Mansij Biswas, Arpit Jain, Jignesh Ved, from Boehringer Ingelheim (India) medical affairs for providing writing assistance for this manuscript in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

**Authorship.** All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

**Author Contributions.** All named authors have contributed equally for each of the sections for developing this expert opinion paper.

**Disclosures.** Manoj Chadha has received honorarium as speaker and advisory board member from Boehringer Ingelheim India, Astra Zeneca, Jansen, Novo Nordisk, Eli Lilly, MSD, and Sanofi-Aventis. Ashok Kumar Das has been speaker and advisory board member for Boehringer Ingelheim India. Prasun Deb has received honorarium as speaker and advisory board member from Boehringer Ingelheim India. Kalyan Kumar Gangopadhyay has received speakership honorarium from Boehringer Ingelheim India, Astra Zeneca, Jansen, Novo Nordisk, and Eli Lilly. Shashank Joshi has received honorarium as speaker and advisory board member from Boehringer Ingelheim India. Jothydev Kesavadev has been in the
Speaker Bureau of Novo Nordisk, Sanofi, Biocon, BL, Merck, Abbott, Lifescan, Medtronic, AstraZeneca, Ascensia, Novartis, and Roche; has been Principal Investigator of clinical trials from Novo Nordisk, Janssen, IPCA, and Roche; and has received research support from Genteel INC. Rajiv Kovil has received honorarium as speaker and advisory board member from Boehringer Ingelheim India. Surender Kumar has been advisory board member of Boehringer Ingelheim India, AstraZeneca, Jansen, Novo Nordisk, Eli Lilly, MSD, Sanofi-Aventis, USV Private Limited, Eris Lifesciences, Lupin Limited, and Roche Diabetes Care India Pvt. Ltd. Anoop Misra has received honorarium from Boehringer Ingelheim, Jannssen, AstraZeneca, Glenmark, Dr Reddy’s Laboratories, and Intas pharmaceuticals. Viswanathan Mohan has acted as consultant and speaker for and received research or educational grants from Abbott, Astra Zeneca, Boehringer Ingelheim, Dr. Reddy's Laboratories, Johnson & Johnson, LifeScan, Lilly, MSD, Novartis, Novo Nordisk, Roche Diabetes Care India Pvt. Ltd, Sanofi-Aventis, USV Private Limited, and other Indian pharmaceutical companies. The views and opinions presented in the manuscript represent the independent evidence-based recommendations of the expert panel of authors; it does not suggest or endorse the views of Boehringer Ingelheim India.

**Compliance with Ethics Guidelines.** This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

**Data Availability.** Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/).

**REFERENCES**

1. Anjana RM, Pradeepa R, Deepa M, et al. The Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study: methodological details. J Diabetes Sci Technol. 2011;5:906–14.

2. Anjana RM, Pradeepa R, Deepa M, et al. ICMR-INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose/impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-India DIABetes (ICMR-INDIAB) study. Diabetologia. 2011;54:3022–7.

3. Hills AP, Arena R, Khunti K, et al. Epidemiology and determinants of type 2 diabetes in south Asia. Lancet Diabetes Endocrinol. 2018;6(12):966–78. https://doi.org/10.1016/S2213-8587(18)30204-3.

4. Gupta YK, Ramachandran SS. Fixed dose drug combinations: Issues and challenges in India. Indian J Pharmacol. 2016;48(4):347–9.

5. Gopinath D, Mathew J, Kalra S. Triple fixed drug combinations in type 2 diabetes. Indian J Endocr Metab. 2015;19(3):311–3.

6. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643–8.

7. Mellbin LG, Wang A, Rydén L. Clinical implications of cardiovascular outcome trials in type 2 diabetes. Herz. 2019;44(3):192–202.

8. Misra A, Bloomgarden Z. Diabetes during the COVID-19 pandemic: a global call to reconnect with patients and emphasize lifestyle changes and optimize glycemic and blood pressure control. J Diabetes. 2020;12:556–7. [https://doi.org/10.1111/1753-0407.13048](https://doi.org/10.1111/1753-0407.13048).
9. Chatterjee S, Davies MJ. Current management of diabetes mellitus and future directions in care. Postgrad Med J. 2015;91:612–21.

10. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S127–38.

11. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, American Association of Clinical Endocrinologists. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive Type 2 Diabetes management algorithm Executive Summary. Endocr Pract. 2019;25(1):69–100.

12. American Diabetes Association. Pharmacologic approaches to glycaemic treatment: Standards of medical care in diabetes. Diabetes Care. 2019;42(Suppl. 1):S90–102.

13. Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol. 2016;12(12):1407–17.

14. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95.

15. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17(3):183–90.

16. Gabbay MAL, Rodacci M, Calliari LE, Vet al. Time in range: a new parameter to evaluate blood glucose control in patients with diabetes. Diabetol Metab Syndr. 2020;12:12.

17. Lee H, Park SE, Kim EY. Glycemic variability impacted by SGLT2 inhibitors and GLP 1 agonists in patients with diabetes mellitus: a systematic review and meta-analysis. J Clin Med. 2021;10(18):4078. https://doi.org/10.3390/jcm10184078.

18. Lee S, Lee H, Kim Y, Kim E. Effect of DPP-IV inhibitors on glycemic variability in patients with T2DM: a systematic review and meta-analysis. Sci Rep. 2019;9(1):13296. https://doi.org/10.1038/s41598-019-49803-9.

19. Kesavadev J, Misra A, Saboo B, et al. Time-in-range and frequency of continuous glucose monitoring: recommendations for South Asia. Diabetes Metab Syndr. 2022;16:102345. https://doi.org/10.1016/jjdsex.2021.102345.

20. Triplitt C, Solis-Herrera C, Cersosimo E, Abdul-Ghani M, DeFronzo RA. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2015;16(18):2819–33.

21. Shah P, Ardestani A, Dharmadhikari G, et al. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab. 2013;98(7):E1163–72.

22. Hocher B, Sharkovsky Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol. 2013;167(1):87–93.

23. Chaykovska L, von Websky K, Rahnenfu¨hrer J, et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS ONE. 2011;6(11):e27861.

24. Doupijs J. Linagliptin: from bench to bedside. Drug Des Devel Ther. 2014;8:431–46.

25. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83–90.

26. Hansen HH, Jelsing J, Hansen CF, et al. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat. J Pharmacol Exp Ther. 2014;350(3):657–64.

27. Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):422–34.

28. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108–17.

29. Mohan V. Why are Indians more prone to diabetes? J Assoc Physicians India. 2004;52:468–74.

30. Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281(1):51–63.

31. Hills AP, Misra A, Gill JMR, Byrne NM, Soares MJ, Ramachandran A, et al. Public health and health systems: implications for the prevention and management of type 2 diabetes in south Asia. Lancet Diabetes Endocrinol. 2018;6(12):992–1002.

32. Anoop S, Misra A, Bhatt SP, et al. High circulating plasma dipeptidyl peptidase-4 levels in non-obese
Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intraabdominal adipose tissue volume and presence of diabetes: a case–control study. BMJ Open Diab Res Care. 2017;5:e000393.

33. Sarashina A, Friedrich C, Crowe S, et al. Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes. J Diabetes Investig. 2016;7(5):744–50.

34. Ning G, Bandgar T, Hennke U, Lee J, Chan JCN. Efficacy and safety of linagliptin in 2681 Asian patients stratified by age, obesity, and renal function: a pooled analysis of randomized clinical trials. Adv Ther. 2017;34(9):2150–62.

35. Gan S, Dawed AY, Donnelly LA, et al. Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2020;43:1948–57.

36. Kaku K, Lee J, Mattheus M, Kaspers S, George J, Woerle HJ. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease—results from EMPA-REG OUTCOME. Circ J. 2017;81(2):227–34.

37. Kadowaki T, Nangaku M, Hantel S, et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME trial. J Diabetes Investig. 2019;10(3):760–70.

38. Singh AK, Unnikrishnan AG, Zargar AH, et al. Evidence-based consensus on positioning of SGLT2i in type 2 diabetes mellitus in Indians. Diabetes Ther. 2019;10(2):393–428.

39. Kawamori R, Haneda M, Suzaki K, et al. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: 52-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2018;20(9):2200–9.

40. Kaku K, Haneda M, Tanaka Y, et al. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: glycemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. Diabetes Obes Metab. 2019;21(1):136–45.

41. US Food Drug and Administration. Drug approvals and databases. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206073Orig1s000TOC.cfm. Accessed 11 May 2020

42. US Food Drug and Administration. Drug approvals and databases. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000TOC.cfm. Accessed 11 May 2020

43. US Food Drug and Administration. Drug approvals and databases. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000TOC.cfm. Accessed 11 May 2020

44. Central Drugs Standard Control Organization (CDSCO). Fixed dose combinations approved by DCG (I) since 1961 to 31st Dec 2019. https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NTQyMw==. Accessed 11 May 2020.

45. Central Drugs Standard Control Organization (CDSCO). Fixed dose combinations approved by DCG (I) from 1st January 2020 to 31st December 2020. https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=Njg0Nw==. Accessed 16 Feb 2021.

46. Kadowaki T, Inagaki N, Kondo K, et al. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study. Diabetes Obes Metab. 2018;20:453–7.

47. Okahata S, Sakamoto K, Mitsumatsu T, Kondo Y, Tanaka S, Shiba T. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase4 inhibitor: results from the CANARIIS Trial using canagliflozin and teneligliptin. Diabetes Obes Metab. 2019;21:388–92.

48. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394–402.

49. Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Therapy. 2018;9(1):253–68.

50. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes: the VERTIS SITA randomised study. Diabetes Therapy. 2018;9(1):253–68.

51. DeFronzo RA, Lee C, Kohler S. Safety and tolerability of combinations of empagliflozin and linagliptin in patients with type 2 diabetes: pooled data from two randomized controlled trials. Adv Ther. 2018;35(7):1009–22.
52. Fadini GP, Bonora BM, Mayur S, Rigato M, Avogaro A. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018;20(3):740–4.

53. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38(3):376–83.

54. Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38(11):2009–17.

55. Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111–20.

56. Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018;9(1):253–68.

57. Min SH, Yoon J-H, Moon SJ, Hahn S, Cho YM. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep. 2018;8:4466.

58. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

59. Neal B, Perkovic V, Mahaffey K, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;376:644–57.

60. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

61. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Maslukiewicz U, Charbonnel B, Frederick R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZ, McGuire DK, Investigators VERTISCV. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425–35. https://doi.org/10.1056/NEJMoa2004967.

62. Seidu S, Kunutsor SK, Cos X, Gillani S, Khunti K. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes. 2018;12(3):265–83.

63. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

64. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

65. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.

66. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. JAMA. 2019;321(1):69–79.

67. McMurray JJ, Ponikowski P, Bolli GB, et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Failure. 2017;6(1):8–17.

68. Pharmaceutical and Medical Devices Agency, Japan. Teneligliptin review report. April 2012. https://www.pmda.go.jp/files/000153594.pdf. Accessed 15 May 2020.

69. Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab. 2014;16:118–23.

70. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53:213–25.

71. Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018;41(8):1801–8.

72. Sattar N, Fitchett D, Hantel S, George JT, Zinman B. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME trial. Diabetologia. 2018;61(10):2155–63.

73. Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind,
placebo-controlled clinical trial. Diabetes Ther. 2021;12:843–61. https://doi.org/10.1007/s13300-021-01011-3.

74. Gangopadhyay KK, Singh P. Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment. Indian J Endocr Metab. 2017;21:341–54.

75. Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012;74(1):75–85.

76. Inagaki N, Sheu WH, Owens DR, et al. Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: a retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials. J Diabetes Complications. 2016;30(8):1622–30.